MINI-REVIEW

Benefits and Harms of Phytoestrogen Consumption in Breast Cancer Survivors

Sadaf Alipour1*, Shahrzad Jafari-Adli2, Amirhossein Eskandari3

Abstract

Worldwide, breast cancer is the most common malignant neoplasm and the second most common cause of cancer death in women. This malignancy is recognized to be estrogen-dependent and due to this feature, hormone replacement therapy is regarded as potentially dangerous in breast cancer survivors who seek relief of their menopausal symptoms. Whereas hot flashes are detected in nearly half of postmenopausal women with a relatively high frequency and severity, botanic sources of estrogens have been proposed as an alternative treatment. Nevertheless, estrogenic properties of these compounds suggest possibility of stimulating cancer recurrence or worsening prognosis in survivors. As well, effects in improving vasomotor climacteric changes is controversial. Many studies have considered the subject, some focusing on efficacy of phytoestrogens for control of menopausal symptoms, and others discussing effects of these compounds on breast cancer outcome in terms of survival or recurrence. The present article is a concise review of the effects of consumption of phytoestrogens on menopausal symptoms, namely hot flashes, and breast cancer recurrence and mortality in survivors of the disease. Overall, the major part of the current existing literature is in favor of positive effects of phytoestrogens on breast cancer prognosis, but the efficacy on menopausal symptoms is probably minimal at the best.

Keywords: Breast - cancer - climacteric - estrogens - menopause - neoplasm - phytoestrogens - tamoxifen

Asian Pac J Cancer Prev, 16 (8), 3091-3096

Introduction

Breast cancer is the most common female malignancy and the second cause of death due to cancer around the world (Fritz et al., 2013). Exogenous and endogenous estrogens are recognized as being associated with the etiology of breast cancer by stimulating cell growth and proliferation; higher and longer lifetime exposure to estrogens could therefore be a major risk factor for promoting or initiating breast cancer (Liu et al., 2005). As a result, apprehension has always accompanied the use of estrogenic compounds in breast cancer survivors; consumption of phytoestrogens, as a type of estrogen, is also associated with much controversy in these women.

Phytoestrogens: Structure, Types, and Functions

Phytoestrogens are secondary polyphenolic plant substances with similarities to 17-beta estradiol in chemical structure (Davis et al., 2008). These are categorized into three main classes: isoflavones, coumestans, and lignans. Isoflavone phytoestrogens are the major active component in soy products (Chen et al., 2003) and are the most widely used group of phytoestrogens consumed. Soybeans and isoflavone-containing foods are found in a variety of fruits, vegetables, and cereal products. After consumption, these substances undergo enzymatic conversion in the gut; isoflavones are metabolized into aglycones, genistein and daidzein, lignans into secoisolariciresinol diglucoside, and coumestans into coumestrol. These metabolites include a phenolic ring that competes for binding to estrogen receptors, which results in weak estrogenic activity, hence the term phytoestrogen (Bedell et al., 2014); daidzein and genistein have been mostly investigated in related studies.

Rate of consumption of these compounds varies greatly in different countries and cultures; highest rates are seen in Asian people, who use approximately 20-50 mg per day of these substances (Mense et al., 2008; Fritz et al., 2013).

Evidence has been unconvincing in providing distinct mechanisms of action of phytoestrogens. The 3-fold lower risk of breast cancer in Asian women compared with their western counterparts, as well as lower serum concentration of estrogen in the former group may be attributed to different lifestyle and diet patterns, including routine use of dietary phytoestrogens (Mense et al., 2008; Fritz et al., 2013). The observation that second- and late-generation offsprings of women who migrated from Asia to Western countries had similar breast cancer risks

1Department of Surgery, Arash Women's Hospital, 2Obesity and Eating Habits Research Center, Endocrinology and Metabolism Molecular - Cellular Sciences Institute, Tehran University of Medical Sciences, 3Deputy of Management and Resource Development, Ministry of Health and Medical Education, Tehran, Iran *For correspondence: sadafalipour@yahoo.com

DOI:http://dx.doi.org/10.7314/APJCP.2015.16.8.3091
to their counterparts in the host country supported this assumption against the contribution of genetic factors (Mense et al., 2008).

Menopausal Symptoms in Breast Cancer Survivors

Menopausal symptoms (MS) are common during peri-menopausal and post-menopausal periods in women (L’Esperance et al., 2013). Some of these symptoms such as hot flashes, night sweats, insomnia, tiredness, depression, vaginal dryness, irritability, anxiety, dyspareunia, decreased libido, leucorrhrea, and vaginal bleeding can deeply and negatively affect women’s quality of life (QOL) (Biglia et al., 2003; Bruno and Feeney 2006). Vasomotor hot flashes, defined as a sudden feeling of severe warmth localized particularly in face and neck areas, occurs in two thirds of postmenopausal healthy women, but there is considerable differences in intensity, frequency, and onset of time of hot flashes in different races and cultures (Loprinzi et al., 2001). Hot flushes reach intolerable levels in 10%-20% of cases (Boekhout et al., 2006).

MS occurs in up to 66% of breast cancer survivors as well, because many cases of breast cancer occur in post-menopausal women, and in premenopausal cases is the result of estrogen withdrawal which happens as the most common side-effect of adjuvant therapies, including chemotherapy and hormone therapy (Biglia et al., 2003). More severe symptoms in these patients, accompanied by higher incidence, and longer time persistence compared with healthy individuals, can greatly reduce their quality of life (Biglia et al., 2003; Boekhout et al., 2006; Bruno and Feeney 2006).

Due to recent improvement in breast cancer treatment and earlier detection of the disease, number of long-term survivors is increasing (Kang et al., 2010), and MS would therefore be a greater problem. Given the importance of the issue of disturbed QOL secondary to increased MS, many studies have been conducted among breast cancer survivors regarding best treatment options (Biglia et al., 2003; Boekhout et al., 2006).

Tamoxifen and Menopausal Symptoms in Breast Cancer Survivors

Estrogens affect breast tissue via estrogen receptors by influencing cell growth and differentiation. Therefore, for its prognostic and therapeutic implications, estrogen receptor status is routinely assessed in breast cancer cells after diagnosis. Hormonal treatments are today one of the most important options in receptor positive tumors; the most frequently used SERM is tamoxifen (Abdulkareem and Zurmi 2012). Former studies had definitely confirmed that a 5 years course of adjuvant tamoxifen decreased disease recurrence and mortality from breast cancer throughout the first 15 years after diagnosis in cases of estrogen receptor positive early breast cancer. Thereafter, the worldwide ATLAS trial (Adjuvant Tamoxifen: Longer Against Shorter), including 12 894 women with early breast cancer who had already received tamoxifen for 5 years, compared the effects of continuing tamoxifen for 5 other years versus stopping at 5 years. Results showed that using tamoxifen for 10 years in ER-positive disease further decreased recurrence and mortality, probably halving mortality during the second decade after diagnosis (Davies et al., 2013). However, as an opponent to estrogen in some other body tissues, tamoxifen also induces some adverse effects. As an estrogen opponent, tamoxifen provokes MS; the most common side effect of tamoxifen is hot flashes, which occurs in nearly half of cases and is generally more severe than in women with naturally occurring menopause in terms of frequency and intensity (Loprinzi et al., 2001).

Treatment Options for Menopausal Symptoms Overall

Hormone replacement therapy (HRT) with synthetic estrogen and progesterone compounds is the first line therapy for MS in healthy women; these not only have the potential to alleviate the entire range of MS, but can also partially protect the patient against osteoporosis and cardiovascular disease (Davis et al., 2008). Despite these benefits, many women prefer not to use HRT because of potential adverse effects such as an amplified risk of deep venous thrombus formation, hepatic disease, and an increased risk of cancer (Bedell et al., 2014).

Some trials have shown that a number of non-medicinal ways such as paced respiration, yoga and exercise, acupuncture and magnet therapy, or homeopathy may have some positive effects on MS (Pinkerton et al., 2009). Some other suggested treatments include selective serotonin reuptake inhibitors (paroxetine (Weber and Thacker 2014), citalopram, and venlafaxine (Handley and Williams 2014), or plant extracts with similar properties (black cohosh and licorice). As well, clonidine, gabapentin, Ginseng, evening primrose, vitamin E have all been used with different results in decreasing MS (Wong et al., 2009). Botanic products with progestogenic activities (red clover and chasteberry) or estrogenic action (phytoestrogens- soy, red clover, licorice) (Hajirahimkhani et al., 2013) are other recommended options. Overall, food sources rich in phytoestrogens, are being used as an alternative to HRT by many women. However, positive effects of phytoestrogenic compounds on MS or even bone loss have not been uniformly demonstrated (Levis et al., 2011), studies have shown that - based on type of intestinal flora, diet antibiotic use, and illness- some women can metabolize phytoestrogenic compounds into effective substances that can successfully reduce MS (Bedell et al., 2014).

Effect of Phytoestrogens on Menopausal Symptoms Overall

Some of the mostly researched alternatives to HRT have been phytoestrogens, especially soy isoflavones, although results of past studies are controversial (Secreto
menopausal women in comparison with 126 controls who received placebo (Levis et al., 2011). In a review carried out by Eden et al in 2012, five meta-analyses and one review about the impact of phytoestrogens on MS were evaluated, and the overall results could not clearly show a benefit for isoflavone use in menopause; the authors conclude that if isoflavones have an impact on hot flushes, it is not much more than placebo (Eden, 2012). However, a large systematic review was performed by taku et al in the same year, assessing the efficacy of soybean isoflavones in the relief of hot flashes in peri- and postmenopausal women. According to their very strict criteria, they could include 19 randomized controlled trials in their review, and concluded that soy isoflavones can significantly reduce hot flushes in the target groups (Taku et al., 2012). In 2014, Thomas et al conducted a systematic review focusing on trials that had studied the effect of isoflavones and amino acids on hot flushes and at least one other MS, and included 17 works in their review. They concluded that isoflavones significantly improved hot flashes and co-occurring symptoms in peri- and postmenopausal periods (Thomas et al., 2014).

### Treatment Options for Menopausal Symptoms in Breast Cancer Survivors

In 1997, a consensus development conference on

---

**Table 1. Summary of Human Studies about Effects of Phytoestrogens on Menopausal Symptoms in Breast Cancer survivors**

| First author- Pub year-type of study | Purpose of study: assessment of … | Number of cases | Type/ dose of PE used | Results |
|-------------------------------------|----------------------------------|-----------------|----------------------|---------|
| Quella et al. 2000 RCT, cross over design | Effect of soy PE on HF in BCS | 149 BCS divided in 2 groups | soy tablets 150 mg soy/d or placebo; 2 periods of treatment for 4 w with 1 w rest in between for cross over | No significant difference between 2 groups |
| Van Patten et al. 2002 RCT | Effect of soy PE on HF in BCS | 59 cases, 64 controls | 500 mL of a soy or placebo beverage | No significant difference between 2 groups |
| Nikander et al. 2003 - RCT, cross over design | Effects of PE on MS and QOL in BCS | 56 BCS divided in 2 groups | PE tablets 114 mg isoflavonoid/d or placebo; 2 periods of treatment for 3 m with 2 m rest in between for cross over | No significant difference between 2 groups |
| MacGregor et al. 2005 - RCT | Effects of soy PE on MS and QOL in BCS | 33 cases, 35 controls | 12 w of soy capsules (overall 70 mg/d of soy PE) or placebo | No significant difference between 2 groups |
| Gold et al. 2006 (WHEL*) - multicenter RCT | Association of MS with soy food, and effects of soy PE on MS, in early stage BCS | Overall 2198 BCS | Soy-rich food in cases, regular diet in controls | No association between use of PE and MS |
| Dorigochoo et al. 2011 - Cohort | Association of MS with soy food | 4842 Chinese BCS | Habitual dietary intake of soy foods was assessed** | No significant association between soy PE intake and MS |
| Pruthi et al. 2012 - RCT | Effects of flaxseed*** on HF | 88 cases, 90 controls **** | Flaxseed bar (providing 410 mg of lignans) for 6 w, or placebo | No significant difference between 2 groups |

*Pub=publication, PE=phytoestrogen, RCT=randomized controlled (clinical) trial, HF=hot flashes, BCS=breast cancer survivors, d=day, w=week, MS=menopausal symptoms, QOL=quality of life, m=month. *WHEL study =Women’s Healthy Eating and Living **This study included participants of the Shanghai Breast Cancer Survival Study (SBCSS) *** the richest source of lignans (one of the major classes of phytoestrogens) ****half in each group were BCS
estrogen-deficiency symptoms concluded that estrogen-replacement therapy should be avoided in patients with a history of recent breast cancer (Treatment of estrogen deficiency symptoms in women surviving breast cancer, Part 6: Executive summary and consensus statement. Proceedings of a conference held at Boar’s Head Inn, Charlottesville, Virginia, September 21-23, 1997. Oncology (Williston Park) 1999;13:859-861, 865-856, 871-852). Although few trials demonstrated breast cancer progression due to HRT (Col et al., 2001; Beral et al., 2003), this treatment modality is still contraindicated in breast cancer survivors due to probable rise or acceleration in tumor cell growth (Biglia et al., 2003).

Severity of irritating symptoms especially hot flashes on one hand, and concern about the safety of therapies including synthetic hormones on the other, encourage these groups of patients to use simple strategies in order to alleviate their symptoms. These approaches include wearing light clothes, lowering room temperature, using air conditioners, and avoiding hot or spicy food (Boekhout et al., 2006). However, the overall efficacy of these behavioral options is modest. In the recent decade, many studies have been conducted to find an effective drug with minimal side effects and low risks to treat these MS in patients surviving breast cancer, hence clinicians must receive a symptom relief treatment that does not affect the efficacy of the regimen. Phytoestrogens can probably be a good option in these cases (Bedell et al., 2014).

In 2002, after implanting MCF-7 cells in ovariectomized athymic mice, Ju et al assessed interactions between genistein (as a soy isoflavone) and tamoxifen on the effect of phytoestrogens in reducing MS has not been confirmed by using phytoestrogens has been controversial in breast cancer survivors. Table 1 summarizes results of some studies about this subject. As demonstrated, efficacy of phytoestrogens in reducing MS not has been confirmed in most studies.

**Effect of Phytoestrogens on Menopausal Symptoms in Breast Cancer Survivors**

As for the general population, improvement of MS by using phytoestrogens has been controversial in breast cancer survivors. Table 1 summarizes results of some studies about this subject. As demonstrated, efficacy of phytoestrogens in reducing MS has not been confirmed in most studies.

**Effect of Phytoestrogens on Menopausal Symptoms in Tamoxifen Users**

Breast cancer survivors undergoing hormone therapy must receive a symptom relief treatment that does not affect the efficacy of the regimen. Phytoestrogens can probably be a good option in these cases (Bedell et al., 2014).

In 2002, after implanting MCF-7 cells in ovariectomized athymic mice, Ju et al assessed interactions between genistein (as a soy isoflavone) and tamoxifen on the growth of these estrogen-dependent breast cancer cells. They found out that genistein lowered the effect of

---

Table 2. **Summary of Human Studies about Effects of Phytoestrogens on Breast Cancer Prognosis**

| Author, year of study, type of study | Purpose of study: assessment of… | Number of cases studied | Type/ dose of PE used | Median Follow up time | Results |
|-----------------------------------|---------------------------------|-------------------------|----------------------|----------------------|---------|
| Shu et al., 2009 Cohort, longitudinal | Association of soy food with BC mortality and recurrence in BCS | 5042 BCS | soy foods commonly used in Shanghai | 3.9 y after Dx | Significant decreased mortality and recurrence with higher soy food intake |
| Guha et al., 2009 (LACE*) --Cohort | Association of soy food with BC recurrence in BCS | 1954 BCS | Several kinds of soy-containing foods | 6.31 y after enrollment | Non-significant decreased recurrence with higher soy food intake |
| Kang et al., 2010 Cohort | Association of soy food with BC mortality and recurrence in BCS | 508 BCS under adjuvant HT | Several kinds of soy-containing foods | 5.1 y after Dx | Significant decreased recurrence with higher soy food intake in postm with ER+, PR+ BC |
| Caan et al., 2011 following (WHEL**) study-Cohort | Effects of soy foods on BC prognosis in BCS | 3088 early stage BCS | Several kinds of soy-containing foods | 7.3 y after enrollment | Significant decreased mortality with higher soy food intake, but non-significant highest level of intake |
| Zhang et al., 2012 Cohort | Association of soy food with BC mortality and recurrence in BCS | 616 BCS | Several kinds of soy-containing foods | 52.1 m after Dx | Significant decreased mortality and recurrence with higher soy food intake esp. in ER+ BC |
| Nechuta et al., 2012 (ABCPP***)- 2 US and 1 Chinese cohort, pooled analysis | Association of soy food with BC mortality and recurrence in BCS | 9514 BCS | Several kinds of soy-containing foods | 7.4 y after Dx | Non-significant decreased mortality and significant decreased recurrence with higher soy food intake |

Pub=publication, PE=phytoestrogen, postm= post-menopausal, BC= Breast Cancer, BCS= breast cancer survivors, y=year, Dx= diagnosis, RCT= randomized controlled (clinical) trial, PE= phytoestrogen, HT= hormone therapy, ER+= estrogen receptor positive, PR+= progesterone receptor positive, m=month, esp.=especially. **LACE = Life After Cancer Epidemiology study. **WHEL= Women’s Healthy Eating and Living study**
Effect of Phytoestrogens on Breast Cancer Prognosis

Some epidemiologic studies have suggested that high consumption of phytoestrogens, mostly soy and unrefined grain products, may lower the risk of some cancers such as colorectal, prostate, and breast cancer. As well, ecological observations have confirmed that the lower incidence of breast cancer among Asian women may be related to the more frequent use of phytoestrogens among them (Mense et al., 2008). As well, mammographic density has not been shown to be affected by soy or phytoestrogen products, and recent in vitro work show either a weak proliferative effect of soy isoflavones on breast cancer cells or the blockage of proliferative effects of estradiol on these cells (Pitkin 2012). Human studies are not uniform in results regarding effects of phytoestrogens on breast cancer in survivors; Table 2 shows a summary of some studies.

Conclusion

Most of the present literature is in favor of the safety of phytoestrogens in breast cancer survivors, and even a protective effect leading to decreased breast cancer recurrence and mortality has been confirmed in a major proportion of relevant studies. Nevertheless, although administration of synthetic female sex hormones has a great efficacy in improving hot flashes and other menstrual symptoms, botanic estrogens have not been shown to exert the same positive effects in controlling these symptoms in breast cancer survivors.

References

Abdulkareem IZ, Zurmi IB. (2012). Review of hormonal treatment of breast cancer. Nigerian J Clin Practice, 15, 9-14.
Albertazzi P, Pansini F, Bonaccorsi G, et al (1998). The effect of dietary soy supplementation on hot flushes. Obstetrics & Gynecology, 91, 6-11.
Antoine C, Liebens F, Carly B, Pastijn A, Rozenberg S (2007). Safety of alternative treatments for menopausal symptoms after breast cancer, A qualitative systematic review. Climacteric, 10, 23-26.
Bedell S, Nachtigall M, Naftolin F (2014). The pros and cons of plant estrogens for menopause. J Steroid Biochem Mol Biol., 139, 225-236.
Beral V, Banks E, Reeves G, Bull D (2003). Breast cancer and hormone-replacement therapy, The million women study. The Lancet, 362, 1330-1.
Biglia N, Cozzarella M, Cacciari F, et al (2003). Menopause after breast cancer, A survey on breast cancer survivors. Maturitas, 45, 29-38.
Boekhout AH, Beijnen JH, Schellens JH (2006). Symptoms and treatment in cancer therapy-induced early menopause. The oncologist, 11, 641-54.
Bruno D, Feeney KJ (2006). Management of postmenopausal symptoms in breast cancer survivors. Seminars in oncology, 33, 696-707.
Brzezinski A, Adlercreutz H, Shaoul R, et al (1997). Short-term effects of phytoestrogen-rich diet on postmenopausal women. Menopause, 4, 89-94.
Burke GL, Legault C, Anthony M, Bland, et al (2003). Soy protein and isoflavone effects on vasomotor symptoms in peri-and postmenopausal women, The soy estrogen alternative study. Menopause, 10, 147-53.
Caan BJ, Natarajan L, Parker B, et al (2011). Soy food consumption and breast cancer prognosis. Cancer Epidemiol Biomarkers Prev, 20, 854-8.
Chen W-F, Huang M-H, Tzang C-H, Yang M, Wong M-S (2003). Inhibitory actions of genistein in human breast cancer (mcf-7) cells. Biochim Biophys Acta, 1638, 187-96.
Col NF, Hirotka LK, Orr RK, et al (2001). Hormone replacement therapy after breast cancer, A systematic review and quantitative assessment of risk. J Clin Oncol, 19, 2357-63.
Constantinou AI, White BE, Tonetti D, et al (2005). The soy isoflavone daidzein improves the capacity of tamoxifen to prevent mammary tumours. Eur J Cancer, 41, 647-54.
Davies C, Pan H, Godwin J, et al (2013). Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer, Atlas, a randomised trial. Lancet, 381, 805-16.
Davis VL, Jayo MJ, Ho A, et al (2008). Black cohosh increases metastatic mammary cancer in transgenic mice expressing c-erb2. Cancer Res, 68, 8377-83.
Dorigochoo T, Gu K, Zheng Y, et al (2011). Soy intake in association with menopausal symptoms during the first 6 and 36 months after breast cancer diagnosis. Breast Cancer Res Treat, 130, 879-89.
Eden JA (2012). Phytoestrogens for menopausal symptoms. A review. Maturitas, 72, 157-9.
Fritz H, Seely D, Flower G, et al (2013). Soy, red clover, and isoflavonoids and breast cancer, A systematic review. PloS One., 8, e18968.
Gold EB, Flatt SW, Pierce JP, et al (2006). Dietary factors and vasomotor symptoms in breast cancer survivors, The WHEL study. Menopause, 13, 423-33.
Guha N, Kwan ML, Queensberry Jr CP , et al (2009). Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors, The life after cancer epidemiology study.
Sadaf Alipour et al

Breast Cancer Res Treat, 118, 395-405.

Hajirahimkhani A, Dietz BM, Bolton JL (2013). Botanical modulation of menopausal symptoms, Mechanisms of action? Planta Medica, 79, 538-53.

Handley AP, Williams M (2015). The efficacy and tolerability of srsi/snsr in the treatment of vasomotor symptoms in menopausal women, A systematic review. J Am Assoc Nurse Practitioners, 27, 54-61.

Ju VH, Doerge DR, Allred KD, Allred CD, Helferich WG (2002). Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (mcf-7) cells implanted in athymic mice. Cancer Res, 62, 2474-7.

Kang X, Zhang Q, Wang S, Huang X, Jin S (2010). Effect of soy isoflavones on breast cancer recurrence and death for patients receiving adjuvant endocrine therapy. Canadian Med Association J, 182, 1857-62.

L’Esperance S, Frenette S, Dionne A, Dionne JY (2013). Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors, Cepo review and recommendations. Supportive Care Cancer, 21, 1461-74.

Levis S, Strickman-Stein N, Ganjei-Azar P et al (2011). Soy isoflavones in the prevention of menopausal bone loss and menopausal symptoms, A randomized, double-blind trial. Arch Int Med, 171, 1363-9.

Liu B, Edgerton S, Yang X, et al (2005). Low-dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumor prevention. Cancer Res, 65, 879-86.

Loprinzi CL, Barton DL, Rhodes D (2001). Management of hot flashes in breast cancer survivors. Lancet Oncol, 2, 199-204.

MacGregor C, Canney P, Patterson G, McDonald R, Paul J (2005). A randomised double-blind controlled trial of oral soy supplements< i> versus</i> placebo for treatment of menopausal symptoms in patients with early breast cancer. Eur J Cancer, 41, 708-14.

Mense SM, Hei TK, Ganju RK, Bhat HK (2008). Phytoestrogens and breast cancer prevention, possible mechanisms of action. Environment Hlth Perspect, 116, 426.

Murkies A, Lombard C, Strauss B et al (1995). Dietary flour supplementation decreases post-menopausal hot flushes, Effect of soy and wheat. Maturitas, 21, 189-95.

Nechuta SJ, Caan BJ, Chen WY et al (2012). Soy food intake after diagnosis of breast cancer and survival, An in-depth analysis of combined evidence from cohort studies of us and chinese women. Am J Clin Nutr, 96, 123-32.

Nikander E, Kilkkinen A, Metsa-Heikkila M et al (2003). A randomized placebo-controlled crossover trial with phytoestrogens in treatment of menopause in breast cancer patients. Obstets Gynecol, 101, 1213-20.

Pinkerton JV, Stovall DW, Kightlinger RS (2009). Advances in the treatment of menopausal symptoms. Women's health (London, England), 5, 361-384; quiz 383-364.

Pitkin J (2012). Alternative and complementary therapies for the menopause. Menopause Int, 18, 20-27.

Pruthi S, Qin R, Terstreip SA et al (2012). A phase iii, randomized, placebo-controlled, double-blind trial of flaxseed for the treatment of hot flashes, Nctg n08c7. Menopause, 19, 48.

Quella SK, Loprinzi CL, Barton DL et al (2000). Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors. A north central cancer treatment group trial. J Clin Oncol, 18, 1068-74.

Scambia G, Mango D, Signorile PG et al (2000). Clinical effects of a standardized soy extract in postmenopausal women, A pilot study. Menopause, 7, 105-111.

Secrcto G, Chiechi LM, Amadori A et al (2004). Soy isoflavones and melatonin for the relief of climacteric symptoms, A multicenter, double-blind, randomized study. Maturitas,